Annual EBITDA:
-$45.85M-$16.65M(-57.00%)Summary
- As of today, RGLS annual EBITDA is -$45.85 million, with the most recent change of -$16.65 million (-57.00%) on December 31, 2024.
- During the last 3 years, RGLS annual EBITDA has fallen by -$19.36 million (-73.07%).
Performance
RGLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
Quarterly EBITDA:
-$9.53M+$3.16M(+24.89%)Summary
- As of today, RGLS quarterly EBITDA is -$9.53 million, with the most recent change of +$3.16 million (+24.89%) on March 31, 2025.
- Over the past year, RGLS quarterly EBITDA has dropped by -$1.23 million (-14.75%).
Performance
RGLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
TTM EBITDA:
-$47.08M-$1.23M(-2.67%)Summary
- As of today, RGLS TTM EBITDA is -$47.08 million, with the most recent change of -$1.23 million (-2.67%) on March 31, 2025.
- Over the past year, RGLS TTM EBITDA has dropped by -$16.47 million (-53.82%).
Performance
RGLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RGLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -57.0% | -14.8% | -53.8% |
| 3Y3 Years | -73.1% | -45.8% | -70.8% |
| 5Y5 Years | -195.3% | -78.8% | -178.6% |
RGLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -73.1% | at low | -45.2% | +31.8% | -71.1% | at low |
| 5Y | 5-Year | -240.8% | at low | -1065.3% | +31.8% | -262.3% | at low |
| All-Time | All-Time | -652.0% | +41.5% | -1229.4% | +56.2% | -6466.0% | +39.9% |
RGLS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$9.53M(+24.9%) | -$47.08M(-2.7%) |
| Dec 2024 | -$45.85M(-57.0%) | -$12.69M(+9.1%) | -$45.85M(-11.7%) |
| Sep 2024 | - | -$13.97M(-28.3%) | -$41.03M(-18.3%) |
| Jun 2024 | - | -$10.89M(-31.1%) | -$34.70M(-13.4%) |
| Mar 2024 | - | -$8.31M(-5.5%) | -$30.61M(-4.8%) |
| Dec 2023 | -$29.20M(-6.2%) | -$7.87M(-3.1%) | -$29.20M(-4.7%) |
| Sep 2023 | - | -$7.63M(-12.3%) | -$27.90M(-1.0%) |
| Jun 2023 | - | -$6.80M(+1.6%) | -$27.61M(+1.0%) |
| Mar 2023 | - | -$6.91M(-5.2%) | -$27.88M(-1.3%) |
| Dec 2022 | -$27.51M(-3.8%) | -$6.57M(+10.6%) | -$27.51M(+1.1%) |
| Sep 2022 | - | -$7.34M(-3.9%) | -$27.82M(+3.6%) |
| Jun 2022 | - | -$7.07M(-8.1%) | -$28.86M(-4.7%) |
| Mar 2022 | - | -$6.54M(+5.0%) | -$27.57M(-4.1%) |
| Dec 2021 | -$26.49M(-96.9%) | -$6.88M(+17.9%) | -$26.49M(-29.7%) |
| Sep 2021 | - | -$8.38M(-45.2%) | -$20.43M(-57.2%) |
| Jun 2021 | - | -$5.77M(-5.7%) | -$12.99M(+4.4%) |
| Mar 2021 | - | -$5.46M(-567.7%) | -$13.59M(-1.0%) |
| Dec 2020 | -$13.46M(+13.4%) | -$818.00K(+13.3%) | -$13.46M(+20.4%) |
| Sep 2020 | - | -$943.00K(+85.2%) | -$16.90M(+18.5%) |
| Jun 2020 | - | -$6.36M(-19.4%) | -$20.73M(-11.0%) |
| Mar 2020 | - | -$5.33M(-25.1%) | -$18.68M(-20.3%) |
| Dec 2019 | -$15.53M(+64.7%) | -$4.26M(+10.8%) | -$15.53M(+16.9%) |
| Sep 2019 | - | -$4.78M(-11.0%) | -$18.68M(+18.8%) |
| Jun 2019 | - | -$4.31M(-97.5%) | -$23.00M(+26.7%) |
| Mar 2019 | - | -$2.18M(+70.6%) | -$31.37M(+28.8%) |
| Dec 2018 | -$44.04M | -$7.42M(+18.5%) | -$44.04M(+11.1%) |
| Sep 2018 | - | -$9.10M(+28.1%) | -$49.56M(+10.1%) |
| Jun 2018 | - | -$12.67M(+14.7%) | -$55.13M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$14.86M(-14.9%) | -$62.93M(+5.9%) |
| Dec 2017 | -$66.86M(+14.7%) | -$12.93M(+11.9%) | -$66.86M(+8.1%) |
| Sep 2017 | - | -$14.67M(+28.4%) | -$72.75M(+4.7%) |
| Jun 2017 | - | -$20.48M(-9.0%) | -$76.37M(+0.0%) |
| Mar 2017 | - | -$18.78M(+0.2%) | -$76.39M(+2.5%) |
| Dec 2016 | -$78.38M(-44.8%) | -$18.82M(-2.9%) | -$78.38M(-18.2%) |
| Sep 2016 | - | -$18.29M(+10.8%) | -$66.34M(-9.3%) |
| Jun 2016 | - | -$20.50M(+1.3%) | -$60.68M(+0.2%) |
| Mar 2016 | - | -$20.77M(-206.4%) | -$60.80M(-12.3%) |
| Dec 2015 | -$54.12M(+1.9%) | -$6.78M(+46.3%) | -$54.12M(+21.7%) |
| Sep 2015 | - | -$12.63M(+38.8%) | -$69.11M(-4.9%) |
| Jun 2015 | - | -$20.63M(-46.4%) | -$65.87M(-15.8%) |
| Mar 2015 | - | -$14.09M(+35.3%) | -$56.86M(-3.1%) |
| Dec 2014 | -$55.15M(-218.9%) | -$21.77M(-131.8%) | -$55.15M(-57.8%) |
| Sep 2014 | - | -$9.39M(+19.2%) | -$34.95M(-27.8%) |
| Jun 2014 | - | -$11.62M(+6.1%) | -$27.36M(-20.4%) |
| Mar 2014 | - | -$12.38M(-687.7%) | -$22.72M(-31.4%) |
| Dec 2013 | -$17.30M(-7.1%) | -$1.57M(+12.5%) | -$17.30M(+22.6%) |
| Sep 2013 | - | -$1.79M(+74.3%) | -$22.35M(+13.6%) |
| Jun 2013 | - | -$6.98M(-0.4%) | -$25.88M(-22.2%) |
| Mar 2013 | - | -$6.95M(-4.8%) | -$21.18M(-31.1%) |
| Dec 2012 | -$16.15M(-164.9%) | -$6.63M(-24.6%) | -$16.15M(-45.3%) |
| Sep 2012 | - | -$5.32M(-133.9%) | -$11.11M(-70.7%) |
| Jun 2012 | - | -$2.27M(-18.0%) | -$6.51M(-53.7%) |
| Mar 2012 | - | -$1.93M(-21.3%) | -$4.24M(-83.6%) |
| Dec 2011 | -$6.10M(+58.6%) | -$1.59M(-121.8%) | -$2.31M(-221.8%) |
| Sep 2011 | - | -$717.00K | -$717.00K |
| Dec 2010 | -$14.73M | - | - |
FAQ
- What is Regulus Therapeutics Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Regulus Therapeutics Inc.?
- What is Regulus Therapeutics Inc. annual EBITDA year-on-year change?
- What is Regulus Therapeutics Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Regulus Therapeutics Inc.?
- What is Regulus Therapeutics Inc. quarterly EBITDA year-on-year change?
- What is Regulus Therapeutics Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Regulus Therapeutics Inc.?
- What is Regulus Therapeutics Inc. TTM EBITDA year-on-year change?
What is Regulus Therapeutics Inc. annual EBITDA?
The current annual EBITDA of RGLS is -$45.85M
What is the all-time high annual EBITDA for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. all-time high annual EBITDA is -$6.10M
What is Regulus Therapeutics Inc. annual EBITDA year-on-year change?
Over the past year, RGLS annual EBITDA has changed by -$16.65M (-57.00%)
What is Regulus Therapeutics Inc. quarterly EBITDA?
The current quarterly EBITDA of RGLS is -$9.53M
What is the all-time high quarterly EBITDA for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. all-time high quarterly EBITDA is -$717.00K
What is Regulus Therapeutics Inc. quarterly EBITDA year-on-year change?
Over the past year, RGLS quarterly EBITDA has changed by -$1.23M (-14.75%)
What is Regulus Therapeutics Inc. TTM EBITDA?
The current TTM EBITDA of RGLS is -$47.08M
What is the all-time high TTM EBITDA for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. all-time high TTM EBITDA is -$717.00K
What is Regulus Therapeutics Inc. TTM EBITDA year-on-year change?
Over the past year, RGLS TTM EBITDA has changed by -$16.47M (-53.82%)